GODAVARI DRUGS LIMITED

Regd. Off.:'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.
Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557
E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

11.11.2026

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Outcome of the Board Meeting held on 11th November, 2026 and submission of the Un-Audited Standalone Financial Results for the quarter and half year ended 30th September, 2026
Ref: Regulations 30, 32 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulations 30 and 33 of the SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. Wednesday, 11th November, 2026, through Video Conferencing, has, inter alia, considered and approved the following:

1. Un-Audited Standalone Financial Results of the Company for the second quarter and half year ended 30th September, 2026, along with the Statement of Assets and Liabilities as at 30th September, 2026 and the Statement of Cash Flows for the half year ended on that date, as reviewed and recommended by the Audit Committee.

2. Limited Review Report issued by the Statutory Auditors, M/s Ayyadevara & Co., Chartered Accountants, on the said Financial Results, as required under Regulation 33 of the SEBI (LODR) Regulations, 2015.

3. Statement of Deviation or Variation in the utilisation of the proceeds of the preferential issue for the quarter ended 30th September, 2026 under Regulation 32 of the SEBI (LODR) Regulations, 2015, as reviewed by the Audit Committee, confirming that there is no deviation or variation.

Copies of the aforesaid Financial Results, the Limited Review Report and the Statement of Deviation or Variation are enclosed herewith. These are also being made available on the website of the Company at www.godavaridrugs.com.

The Board Meeting commenced at 04:15 P.M. and concluded at 05:00 P.M.

This is for your information and records.

Thanking You,
For **Godavari Drugs Limited**
Achanta Venkatesh
Digitally signed by Achanta Venkatesh
Date: 2026.11.11 17:13:43 +05'30'
Venkatesh Achanta
Company Secretary & Compliance Officer
Membership No.: A53326

Encl.: As above

GODAVARI DRUGS LIMITED

CIN : L21001TG1987PLC008016
Regd Office : "Mayfair" S.P.Road, Secunderabad

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2026

Rupees in Lakhs

Sl. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1	**Revenue from operations**	**2822.60**	2795.72	2664.94	**5618.32**	**5046.07**	10580.81
2	Other Income	**-12.09**	15.10	63.54	**3.01**	**64.76**	80.51
3	**Total Revenue from operations (1+2)**	**2810.51**	**2810.82**	**2728.48**	**5621.33**	**5110.83**	**10661.32**
4	**Expenses**						
	(a) Cost of materials consumed	**1880.99**	2614.88	2399.24	**4495.87**	**4198.17**	8888.89
	(b) Changes in inventories of finished goods & work-in-progress	**138.57**	-634.45	-388.23	**-495.88**	**-473.64**	-1139.13
	(c) Employee benefits expense	**159.89**	147.68	144.28	**307.57**	**279.95**	569.66
	(d) Depreciation & amortization expense	**60.78**	59.28	60.37	**120.06**	**120.80**	243.21
	(e) Finance Costs	**83.93**	89.61	90.84	**173.54**	**191.30**	397.97
	(f) Other Expenses	**363.30**	416.09	309.85	**779.39**	**551.89**	1229.93
	Total expenses	**2687.46**	**2693.09**	**2616.35**	**5380.55**	**4868.47**	**10190.53**
5	Profit before exceptional Items and tax (3-4)	**123.05**	117.73	112.13	**240.78**	242.36	470.79
6	Exceptional items						35.51
7	**Profit before Tax (5+6)**	**123.05**	**117.73**	**112.13**	**240.78**	**242.36**	506.30
8	**Tax expense**	**-27.33**	-6.82	-12.06	**-34.15**	**-38.23**	-97.39
9	**Net Profit for the period (7-8)**	**95.72**	**110.91**	**100.07**	**206.63**	**204.13**	**408.91**
10	**Other Comprehensive Income**						
	(i) Items that will not be reclassified to profit or loss	-	-	-	-		-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	-	-	-	-		-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-		-
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-		-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-		-
11	**Total Comprehensive Income (9+10)**	**95.72**	**110.91**	**100.07**	**206.63**	**204.13**	**408.91**
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	**1091.41**	1012.74	1012.74	**1091.41**	**753.05**	1012.74
13	Other Equity as shown in the Audited Balance Sheet of the previous year						6042.04
14	**Earnings per share**						
	(a) Basic	0.94	1.10	1.33	2.04	2.71	5.43
	(b) Diluted	0.90	1.10	1.33	2.00	2.71	5.36

1) The above results , as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on November 11, 2026

2) The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable

3) The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30 th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5 th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.

4) Corresponding figures in previsous year / period have been regrouped wherever considered necessary.

5) EPS of current quarter is based on paid up capital of Rs.1091.41lakhs/- as against 753.05 Lakhs/- as on 30.09.2025

For GODAVARI DRUGS LIMITED

Mohit Jaju
Wholetime Director & CFO
DIN: 03405414

GODAVARI DRUGS LTD. SEC'BAD

Place: Secunderabad
Date : 11.11.2026

GODAVARI DRUGS LIMITED

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30.09.2026

Rupees in lakhs

Particulars	Half Year ended (30.09.2026) (Unudited)	Year ended (31.03.2026) (Audited)
A. Cash Flow from Operating Activities		
Profit before Depreciation, Interest and Tax	534.38	1,147.49
Less : Other Income considered separately	(3.02)	(80.51)
Net	531.36	1,066.98
(Increase) / Decrease in Inventories	(263.82)	(1,812.29)
(Increase) / Decrease in Receivables	512.83	(125.75)
(Increase) / Decrease in Shorttem Loans & Advances	(3.99)	21.31
(Increase) / Decrease in Other Current Assets	(12.69)	(173.06)
Increase / (Decrease) in Current Liabilities	(264.55)	1,215.20
Income Tax Paid	(109.21)	(119.03)
Total A	389.93	73.36
B. Cash Flow from Investing Activities		
(Increase)/Decrease in Fixed Assets	(1,201.26)	(2,672.31)
(Increase)/Decrease in Nonr current assets.	(0.41)	(3.00)
Other Income	3.02	80.51
Total B	(1,198.65)	(2,594.80)
C. Cash Flow from Financing Activities		
Increase in Share Capital	78.67	259.69
Increase in Share Premium	446.45	2,051.58
Increase in Share Warrants	-	525.11
Increase/(Decrease) in Long Term Borrowings	(658.23)	1,307.61
Increase/(Decrease) in Long Term Provisions	(2.10)	(10.98)
Interest Paid	(173.54)	(397.97)
Total C	(308.75)	3,735.04
D. Net Increase/(Decrease) in cash and cash equivalents [	(1,117.47)	1,213.60
Cash and cash equivalents at the beginning of the year	1,450.93	237.33
Cash and cash equivalents at the end of the Period (20.02	333.46	1,450.93
Increase/(-)Decrease	(1,117.47)	1,213.60

For GODAVARI DRUGS LIMITED

Mohit Jaju
Wholetime Director & CFO
DIN: 03405414

GODAVARI DRUGS LTD. SEC'BAD

Place: Secunderabad
Date : 11.11.2026

GODAVARI DRUGS LIMITED

CIN : L21001TG1987PLC008016
Regd Office : 'Mayfair" S.P.Road, Secunderabad
Statement of Assets and Liabilities

Particulars	Rupees in Lakhs	
	Half Year ended (30.09.2026)	Year ended (31.03.2026)
	(UnAudited)	(Audited)
ASSETS		
1. Non - current assets		
a. Property, plant and equipment	2927.22	3030.78
b. Capital work - in -progress	6838.57	5653.82
c. Investment Property		
d. Goodwill		
e. Other Intangible assets		
f. Intangible assets under development		
g. Biological Assets other than bearer plants		
h. Financial Assets		
(i) Investments	0.01	0.01
(ii) Trade Receivables		
(iii) Loans		
(iv) Other Financial assets	179.26	178.85
i. Deferred tax assets (net)		
j. Other non-current assets		
2. Current assets		
(a) Inventories	4870.23	4606.41
(b) Financial Assets		
(i) Investments		
(ii) Trade Receivables	3845.27	4358.11
(iii) Cash and cash equivalents	333.46	1450.93
(iv) Bank balances other than (iii) above		
(v) Loans	84.90	80.90
(vi) Others (to be specified)		
(c) Current Tax Assets (Net)		
(d) Other current assets	696.03	683.32
Total Assets	19774.95	20043.13
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share capital	1091.41	1012.74
(b) Other Equity	6695.12	6042.04
(c) Money Received against Share Warrants	525.11	525.11
LIABILITIES		
1. Non - current liabilities		
(a) Financial Liabilities		
(i) Borrowings	3038.91	3697.13
(ii) Trade payables		
(iii) Other financial liabilities (other than those specified in item (b)		
(b) Provisions	69.56	71.66
(c) Deferred tax liabilities (Net)	173.14	180.02
(d) Other non-current liabilities		
2. Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	5089.97	3938.71
(ii) Trade payables		
(1) Total outstanding dues of microenterprises and small enterprises	16.76	73.86
(2) Total outstanding dues of creditors other thanmicroenterprises and small enterprises	1938.74	3397.54
(iii)Other financial libilities (Other than specified in (c)		
(b) Other current liabilities	1095.20	995.10
(c) Provisions		
(d) Current Tax Liabilities (Net)	41.03	109.22
Total Equity and Liabilities	19774.95	20043.13

For GODAVARI DRUGS LIMITED

Mohit Jaju
Wholetime Director & CFO
DIN: 03405414

GODAVARI DRUGS LTD. SECBAD

Place: Secunderabad
Date : 11.11.2026

Ayyadevara & Co.
Chartered Accountants

1-2-386/A/1, Gagan Mahal
Hyderabad - 500 029
Ph: +91-40-27632354, 27642952
e-mail: sridevar@yahoo.co.in
URL: www.ayyadevara.com

Independent Auditor's Review Report on unaudited Quarter and Half Year ended financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Godavari Drugs Limited
Secunderabad.

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter and half year ended 30th September 2026 (the statement), This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepare policies hance with applicable acccounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 00278S

Ayyadevara Srinivas
Proprietor
Membership No.028803
Secunderabad, Date: 11/11/2026
UDIN: 26028803GIGXZZ4029

AYYADEVARA & Co. * 1-2-386/A/1, Gagan Mahal, Hyd-29. * CHARTERED ACCOUNTANTS

Plant : A 6/2, MIDC, Nanded - 431 603. Maharashtra, India. | E-mail : nnd@godavaridrugs.com
CIN:L24230TG1987PLC008016

GODAVARI DRUGS LIMITED
Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.
Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557
E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

GODAVARI DRUGS LIMITED

Scrip Code: 530317 | ISIN: INE362C01012

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc.

[Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

For the quarter ended 30th September, 2026

(Amount in Lakhs)

Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	-
Date of Raising Funds	18-03-2026
Amount Raised	4,411.73
Report filed for Quarter ended	30-09-2026
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	-
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	-
If Yes, Date of shareholder Approval	-
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	Nil
Comments of the auditors, if any	Nil

Objects for which funds have been raised and where there has been a deviation, in the following table:

For GODAVARI DRUGS LTD.

Managing Director

GODAVARI DRUGS LTD. SEC'BAD

GODAVARI DRUGS LIMITED
Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.
Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557
E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com
Plant : A 6/2, MIDC, Nanded - 431 603. Maharashtra, India. | E-mail : nnd@godavaridrugs.com
CIN:L24230TG1987PLC008016

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	Capital Expenditure for the purpose of manufacturing Active Pharmaceutical Ingredients and intermediates, specialty chemicals in various therapeutic categories including Anti HIV and CNS segments as detailed below: a) Civil construction for production blocks, utilities, platforms, supports, foundations for equipments including finishing consisting of flooring, painting, etc.; b) Procurement and installation of equipments like reactors, heat exchangers, filtration equipments, dryers, pumps, pipelines and fittings, structural steel, safety equipments, fire fightingequipments, enhancement of capacity and upgradation of effluent treatment facilities, etc.; c) Augmenting the electrical infrastructure right from incoming line from substation to transformer and distribution upto the equipments consisting of transformers, electrical pannels, cables, lighting, earthing, etc. Erection and commissioning of all the above	Not Applicable	11,00.00	0.00	796.31	0.00	-
2	Working Capital Requirement	Not Applicable	1,711.73	0.00	0.00	0.00	-
3	Repayment of unsecured loans to promoters and / or Directors	Not Applicable	1,600.00	0.00	400.00	0.00	-

For GODAVARI DRUGS LTD.

GODAVARI DRUGS LTD. SEC'BAD

Managing Director

Signatory Details

Name of signatory	Mukund Kakani
Designation of person	Managing Director
Place	Secunderabad
Date	11-11-2026